drugset
drugset / Trial / NCT05428696

Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants

NCT05428696 ↗

Phase 1 Completed 90 enrolled Alexion Pharmaceuticals, Inc. Celerion · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is designed to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ALXN2080 in healthy adult participants.

Timeline

Start
2022-09-12
Primary completion
2023-04-24
Completion
2023-05-26

Drugs

EvaluationDrugModalityDoseRoute
Subject ZORACOPAN Small molecule — —

Indications

No indication recorded.